Navigation Links
ReceptorBio Announces Diabetes License Agreement With Telik
Date:8/19/2008

side effects," added David Klonoff, M.D., ReceptorBio's Co-founder and Chairman of its Clinical Advisory Board. "A drug that acts by targeting and activating the insulin receptor should provide a novel treatment for this disease, both as a single agent, and in combination with other drugs that have complimentary mechanisms of action."

ReceptorBio, Inc. is an early stage biopharmaceutical company located in Foster City, CA with plans to develop orally active pharmaceuticals for the treatment of T2D and related diseases including obesity, and the insulin resistance/metabolic syndrome which has been associated with a markedly increased risk of cardiovascular disease. The Company's initial focus will be on the clinical development of its lead compound, RB101, believed to activate the insulin receptor tyrosine kinase (IRTK), a recognized drug target for T2D. IRTK activation is one of the early signaling events required to mediate insulin's physiologically effects on glycemic control. Currently, there are no FDA-approved drugs that have this mechanism of action. ReceptorBio believes its novel agents are thus positioned to be first in their class, with a mechanism of action that may be compatible for use both as a single agent and in combination with existing medications for T2D.

The founders and management team of ReceptorBio have a long and successful history of accomplishments in T2D research and drug development. Joseph L. Evans, Ph.D., ReceptorBio President, has over twenty years experience in the research, development, and pharmacology of therapeutics for T2D and obesity, including positions of increasing responsibility in drug discovery and development at Sandoz (now Novartis), Shaman, SUGEN, Telik, and Leptogen. David Klonoff, M.D., FACP, ReceptorBio Director and Chairman of the Clinical Advisory Board, is a Clinical Professor of Medicine at the University of California, San Francisco. In addition, Dr. Klonoff is Medical Director of the Dorothy L. and
'/>"/>

SOURCE ReceptorBio, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for Cancer Therapy Based on Targeting a Biomarker by Novel Investigational Agents
2. ArunA Biomedical Announces Exclusive Worldwide Technology Licensing Agreement to Commercialize Human Embryonic Stem Cell Derived Mesenchymal Cells
3. Arno Therapeutics Announces Second Quarter 2008 Financial Results
4. 4C Controls Announces the Appointment of Dr. Philip Hayden as Vice President, Security Assessment & Threat Analysis
5. Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug
6. Lotus Pharmaceuticals Announces Second Quarter 2008 Results
7. Yongye Biotechnology International Announces Second Quarter Results
8. China Kangtai Cactus Biotech Announces Record Second Quarter Results
9. AMDL Inc. Announces Second Quarter 2008 Results; Company Posts $5.8 Million in Sales With a Revenue Increase of 140%
10. CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award
11. Arno Therapeutics Announces Appointment of Brian Lenz, CPA as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Aug. 27, 2014   MSC , a healthcare ... today announced the appointment of Mary Beth Loesch ... 28 years of experience preparing companies for rapid growth ... Executive Vice President of Corporate Development and Healthcare. In ... business , as well as corporate strategy and marketing. ...
(Date:8/27/2014)... NEW YORK , Aug. 27, 2014 /PRNewswire/ ... report is available in its catalogue: ... http://www.reportlinker.com/p02316662/Global-Chelating-Agents-Market-2014-2018.html About Chelating Agent ... can form covalent bonds with metal ions, thereby ... effect that some metal-ions have on chemical processes, ...
(Date:8/27/2014)... , Aug. 27, 2014  A novel ... to help physicians better identify early-stage disease, when ... disability, according to a new study in The ... Diagnostics (NYSE: DGX ) and other ... 14-3-3eta protein outperformed conventional antibody-serum testing, including rheumatoid ...
(Date:8/27/2014)... , Aug. 27, 2014 Reportbuyer.com has ... The Graphene Opportunity - A Rational View ... The New Nanotech? A similar amount of ... applications ranging from microelectronics to water treatment, but ... the availability of the Graphene Opportunity Report, authored ...
Breaking Biology Technology:MSC names Mary Beth Loesch President and CEO 2Global Chelating Agents Market 2014-2018 2Global Chelating Agents Market 2014-2018 3Global Chelating Agents Market 2014-2018 4Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 2Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 3Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 4The Graphene Opportunity - A Rational View 2The Graphene Opportunity - A Rational View 3The Graphene Opportunity - A Rational View 4
... AFFiRiS AG announced today that Ali Alloueche is ... This new management position has been established as a ... biopharmaceutical company. As a member of the management team, ... of AFFiRiS AG. Before joining AFFiRiS, Ali Alloueche was ...
... December 2, 2011 Cross reference: ... and can be downloaded free of charge at:   ... report in Science from 2008, Dr. Andrew ... Canada, described how chemicals used as manufacturing additives can ...
... Northwest Biotherapeutics (OTC.BB: NWBO) (Northwest Bio) announced today ... balance sheet, removing $31.5 million of liabilities through settlement, ... ) This restructuring reduces the ... the third quarter to $16.5 million. Only about $2.3 ...
Cached Biology Technology:AFFiRiS AG Invests Into Human Capital - Chief Business Officer Recruited 2AFFiRiS AG Invests Into Human Capital - Chief Business Officer Recruited 3Eppendorf Video Features Dr Andrew Holt's Work on Bioactive Leachates From Plastic Consumables 2Northwest Bio Implements Major Balance Sheet Clean-Up 2Northwest Bio Implements Major Balance Sheet Clean-Up 3Northwest Bio Implements Major Balance Sheet Clean-Up 4Northwest Bio Implements Major Balance Sheet Clean-Up 5
(Date:8/27/2014)... the long-standing belief that a deficiency in serotonin ... central role in depression. In the journal ACS ... ability to make serotonin in their brains (and thus ... show depression-like symptoms. , Donald Kuhn and colleagues ... Wayne State University School of Medicine note that depression ...
(Date:8/27/2014)... that health advocates, campaigns against trans-fats have largely ... they,re taking aim at sugar for its potential ... policymakers are still wrangling over the best way ... to an article in Chemical & Engineering ... the American Chemical Society. , In the article, ...
(Date:8/27/2014)... shown that piglets can be weaned later with no ... of the study at the University,s Roseworthy campus, published ... an important finding for pig producers. It allows improvements ... , "Sows don,t usually start their oestrous cycles again ... have been weaned," says Ms Alice Weaver, PhD candidate ...
Breaking Biology News(10 mins):New study throws into question long-held belief about depression 2Piglet weaning age no bar to litter frequency 2
... 20 Quest Diagnostics Incorporated (NYSE: DGX ), the ... that for the third quarter ended September 30, 2009, income ... diluted share, from $160 million, or $0.81 per diluted share, ... results were reduced by a $0.03 per share charge associated ...
... GenVault Corporation, the leader in ambient temperature biosample ... that David Wellis, Ph.D., GenVault,s President and CEO, will ... on October 26th and 27th in La Jolla, CA. ... overview of the company together with recent customer, technical ...
... GenVault Corporation (Carlsbad, CA) today announces that William Brody, ... Brody, the Irwin Jacobs Presidential Chair of the Salk Institute, ... joining the Salk Institute, Dr. Brody served as president of ... the National Academy of Engineering and the Institute of Medicine, ...
Cached Biology News:Quest Diagnostics Reports Strong Performance in Third Quarter 2009 2Quest Diagnostics Reports Strong Performance in Third Quarter 2009 3Quest Diagnostics Reports Strong Performance in Third Quarter 2009 4Quest Diagnostics Reports Strong Performance in Third Quarter 2009 5Quest Diagnostics Reports Strong Performance in Third Quarter 2009 6Quest Diagnostics Reports Strong Performance in Third Quarter 2009 7Quest Diagnostics Reports Strong Performance in Third Quarter 2009 8Quest Diagnostics Reports Strong Performance in Third Quarter 2009 9Quest Diagnostics Reports Strong Performance in Third Quarter 2009 10Quest Diagnostics Reports Strong Performance in Third Quarter 2009 11Quest Diagnostics Reports Strong Performance in Third Quarter 2009 12Quest Diagnostics Reports Strong Performance in Third Quarter 2009 13Quest Diagnostics Reports Strong Performance in Third Quarter 2009 14Quest Diagnostics Reports Strong Performance in Third Quarter 2009 15Quest Diagnostics Reports Strong Performance in Third Quarter 2009 16Quest Diagnostics Reports Strong Performance in Third Quarter 2009 17GenVault Corporation to Present at the 2009 BIOCOM Investor Conference 2Dr. William Brody, President of the Salk Institute for Biological Studies, Appointed to GenVault's Board of Directors 2Dr. William Brody, President of the Salk Institute for Biological Studies, Appointed to GenVault's Board of Directors 3
Homo sapiens HCLS1 associated protein X-1 Antigen: Recombinant Protein...
5,6 Carboxyfluorescein is conjugated to BSA (bovine serum albumin) protein through amide bonds....
MOUSE ANTI BOVINE WC1:FITC Immunogen: Bovine lymphocytes...
B.D. Hames and D.M. Glover (1996) • This issue covers T-Cell antigen receptor genes; T-Lymphocyte signal transduction; B-Cell activation antibody engineering and the complement system and other ...
Biology Products: